Roche Holding AG (RHHBY)
| Previous close | 40.74 |
| Open | 40.93 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 40.72 - 41.16 |
| 52-week range | 39.32 - 53.86 |
| Volume | |
| Avg. volume | 2,437,425 |
| Market cap | 284.082B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | 18.60 |
| EPS (TTM) | 2.21 |
| Earnings date | N/A |
| Forward dividend & yield | 1.24 (3.12%) |
| Ex-dividend date | 17 Mar 2022 |
| 1y target est | 58.30 |
- Globe Newswire
New pivotal data demonstrate clinical benefit of Roche’s glofitamab, a potential first-in-class bispecific antibody for people with aggressive lymphoma
Data to be presented for the first time at ASCO and EHA 2022 show glofitamab induces high and durable complete response rates in people with heavily pre-treated diffuse large B-cell lymphoma 1Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphomaGlofitamab is part of Roche’s industry-leading CD20xCD3 bispecific antibody development programme, which aims to address the diverse needs and preferen
- Business Wire
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
SOUTH SAN FRANCISCO, Calif., May 26, 2022--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new pivotal data on its investigational CD20xCD3 T-cell engaging bispecific antibody, glofitamab, will be presented for the first time at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 and the European Hematology Association (EHA) 2022 Congress from June 9-12. Data from the Phase II NP30179 expansion study demonstrated that, afte
- Zacks
Roche (RHHBY) Gets EC Approval for Polivy Combination in DLBCL
Roche's (RHHBY) Polivy combination receives the European Commission's approval for patients with previously untreated diffuse large B-cell lymphoma.
